Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891132037> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2891132037 endingPage "e15546" @default.
- W2891132037 startingPage "e15546" @default.
- W2891132037 abstract "e15546 Background: In cancer patients, the affected microenvironment causes metabolic insufficiency of terminal CD8+ T cells, characterized by persistent loss of mitochondrial function and mass, typically following progressive loss of PPAR-gamma co-activator 1 alpha (PGC-1α). Consequently, terminal CD8+T cells become exhausted CD8+ T cells expressing PD-1 molecule. According to recent reports, nivolumab may not be effective for the exhausted CD8+ T cells with mitochondrial dysfunction. Hydrogen gas is reported to activate PGC-1α and enhance mitochondrial function, thereby potentially restoring the exhausted CD8+ T cells and improving the clinical efficiency of nivolumab. Methods: Using flow cytometry, we investigated PD-1 expression in CD8+ T cells in the peripheral blood of 55 patients with stage IV colorectal carcinoma, before and after hydrogen gas treatment. Further, we compared the progression-free survival (PFS) and overall survival (OS), using Cox and Kaplan-Meier survival analyses, between 12 patients treated with nivolumab only, and 14 patients treated with nivolumab + hydrogen gas. Results: Hydrogen gas reduced the number of terminal PD-1+CD8+ T cells in 35 of 55 patients and increased terminal PD-1−CD8+ T cells in 39 of 55 patients. Multivariate analyses demonstrated that the ratio of terminal PD-1+CD8+ T cells before and after treatment with hydrogen gas (terminal PD-1+CD8+ T cell ratio) was an independent predictor of PFS [hazard ratio (HR) 6.459, 95 % confidence interval (CI) 2.384–17.50, p < 0.0001] and OS (HR 2.957, 95 % CI 1.185–7.378, p = 0.020). Additionally, patients with higher terminal PD-1+CD8+ T cell ratio had shorter survival rates than those with lower ratio (log rank test, p < 0.0001 for PFS, p = 0.004 for OS), whereas the high terminal PD-1−CD8+ T cell ratio corresponded to longer survival rates than the lower ratio (log rank test, p = 0.004 for PFS, p = 0.024 for OS). Patients treated with nivolumab + hydrogen gas showed a significantly longer OS than those treated with nivolumab only. Conclusions: These results suggest that hydrogen gas restored terminal PD-1+CD8+ T cells to improve PFS and OS in patients with colorectal carcinomas and to enhance clinical effects in those treated with nivolumab, possibly by activating mitochondrial function." @default.
- W2891132037 created "2018-09-27" @default.
- W2891132037 creator A5057126964 @default.
- W2891132037 date "2018-05-20" @default.
- W2891132037 modified "2023-09-25" @default.
- W2891132037 title "Immunological effect of hydrogen gas." @default.
- W2891132037 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.e15546" @default.
- W2891132037 hasPublicationYear "2018" @default.
- W2891132037 type Work @default.
- W2891132037 sameAs 2891132037 @default.
- W2891132037 citedByCount "0" @default.
- W2891132037 crossrefType "journal-article" @default.
- W2891132037 hasAuthorship W2891132037A5057126964 @default.
- W2891132037 hasConcept C121608353 @default.
- W2891132037 hasConcept C126322002 @default.
- W2891132037 hasConcept C153911025 @default.
- W2891132037 hasConcept C154317977 @default.
- W2891132037 hasConcept C167672396 @default.
- W2891132037 hasConcept C185592680 @default.
- W2891132037 hasConcept C202751555 @default.
- W2891132037 hasConcept C203014093 @default.
- W2891132037 hasConcept C207103383 @default.
- W2891132037 hasConcept C2777701055 @default.
- W2891132037 hasConcept C2780030458 @default.
- W2891132037 hasConcept C44249647 @default.
- W2891132037 hasConcept C502942594 @default.
- W2891132037 hasConcept C553184892 @default.
- W2891132037 hasConcept C55493867 @default.
- W2891132037 hasConcept C71924100 @default.
- W2891132037 hasConcept C86803240 @default.
- W2891132037 hasConcept C8891405 @default.
- W2891132037 hasConceptScore W2891132037C121608353 @default.
- W2891132037 hasConceptScore W2891132037C126322002 @default.
- W2891132037 hasConceptScore W2891132037C153911025 @default.
- W2891132037 hasConceptScore W2891132037C154317977 @default.
- W2891132037 hasConceptScore W2891132037C167672396 @default.
- W2891132037 hasConceptScore W2891132037C185592680 @default.
- W2891132037 hasConceptScore W2891132037C202751555 @default.
- W2891132037 hasConceptScore W2891132037C203014093 @default.
- W2891132037 hasConceptScore W2891132037C207103383 @default.
- W2891132037 hasConceptScore W2891132037C2777701055 @default.
- W2891132037 hasConceptScore W2891132037C2780030458 @default.
- W2891132037 hasConceptScore W2891132037C44249647 @default.
- W2891132037 hasConceptScore W2891132037C502942594 @default.
- W2891132037 hasConceptScore W2891132037C553184892 @default.
- W2891132037 hasConceptScore W2891132037C55493867 @default.
- W2891132037 hasConceptScore W2891132037C71924100 @default.
- W2891132037 hasConceptScore W2891132037C86803240 @default.
- W2891132037 hasConceptScore W2891132037C8891405 @default.
- W2891132037 hasIssue "15_suppl" @default.
- W2891132037 hasLocation W28911320371 @default.
- W2891132037 hasOpenAccess W2891132037 @default.
- W2891132037 hasPrimaryLocation W28911320371 @default.
- W2891132037 hasRelatedWork W2044230226 @default.
- W2891132037 hasRelatedWork W2119954546 @default.
- W2891132037 hasRelatedWork W2222086386 @default.
- W2891132037 hasRelatedWork W2572837865 @default.
- W2891132037 hasRelatedWork W2620342065 @default.
- W2891132037 hasRelatedWork W2998555149 @default.
- W2891132037 hasRelatedWork W3149571937 @default.
- W2891132037 hasRelatedWork W4205224142 @default.
- W2891132037 hasRelatedWork W4285595104 @default.
- W2891132037 hasRelatedWork W4308147535 @default.
- W2891132037 hasVolume "36" @default.
- W2891132037 isParatext "false" @default.
- W2891132037 isRetracted "false" @default.
- W2891132037 magId "2891132037" @default.
- W2891132037 workType "article" @default.